Mabion (MAB) Company presentation summary

Company overview and strategy

• Operates as a biologics-focused CDMO with 18 years of experience in developing and manufacturing biological medicines, offering comprehensive services from cell line establishment to commercial manufacturing.

• Holds GMP and ISO certifications, with a modern, scalable production and analytical infrastructure and a multidisciplinary leadership team.

• Implements a 2025-2030 strategy focused on technology, operational excellence, and portfolio diversification, aiming for break-even and profitability by end of 2026.

• Targets growth through co-development partnerships, continuous manufacturing, and expanding into high-potential biotech markets globally.

Service offering and market positioning

• Provides a full range of CDMO services, including process development, drug substance and product manufacturing, analytics, and formulation development for clinical and commercial phases.

• Focuses on strategic projects such as biosimilars, CD20, ADCs, bispecifics, and animal health, with a shift toward co-development and risk-sharing business models.

• Serves small and mid-sized biotech companies globally, with a growing client base in Europe, MENA, Asia, and the USA.

• Market trends favor growth in biologics CDMO due to increasing demand, complexity, and outsourcing needs in biotherapeutics.

Financial performance and outlook

• Revenue has grown each quarter but remains insufficient to cover operating costs; Q3 2025 revenue was PLN 4.1 million, mainly from CDMO services.

• Maintains control over operating costs, with a gross profit margin above 70% in recent quarters, but EBITDA and net profit remain negative.

• Cash position at end Q3 2025 was PLN 4.6 million, requiring additional financing; debt levels are low and mainly consist of loans and leases.

• Project pipeline includes 21 open sales processes and 98 bids submitted since 2023, with a probability-weighted active bid value of USD 50.7 million as of November 2025.

• Revenue potential estimated at EUR 15–20 million annually by 2026, rising to over EUR 25 million by 2028, with a focus on securing financing and achieving operational excellence.